ClinicalTrials.gg
RecruitingNCT07207642Sweet nightMDCUpdated Jan 26, 2026

Sweet Night (Musical Diffusion by Caregivers ): Effects of Musical Diffusion by Caregivers on Sleep Onset and Behavioral Regulation in a Protected Living

An observational study in Alzheimer Disease or Associated Disorder, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
120
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne — 3 open to participants now, 3 under way, none of them phase 3. Alzheimer Disease · Centre Hospitalier Universitaire de Saint Etienne.

Started
2026
with 2 others
Observational
3 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, this one is one of 3 that started in 2026, is one of 3 observational ones, and was the 9th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, or all of them as a file.
02

Study summary

As the Alzheimer's disease progresses, caregivers and family members often focus on behavioral difficulties. In response to crises, immediate actions tend to favor restraints, either through medication or physical means. This work aims to improve the management of behavioral disturbances in patients with Alzheimer's disease through musical interventions (group or individual), particularly in advanced stages of the disease, where medical and family resources are insufficient. The investigators approach prioritizes NTM over medication as a mean to improve patient well-being. To this end, they have designed a study. The study focuses on creating a conducive environment for sleep by incorporating ritualized, familiar music sessions supervised by nursing staff after meals. To conduct this study, the actigraphy will be used to analyze participants' behavior both day and night, complemented by questionnaires and clinical observations.

03

Conditions studied

  • Alzheimer Disease or Associated Disorder

Keywords

  • Alzheimer's disease
  • Music intervention
  • Behavior disorder
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 60 and over, meeting the diagnostic criteria for Alzheimer's disease and related disorders, living in a Protected Living Unit (PLU) will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-opposition of the patient's legal guardian.
  • Patients aged 60 and over, meeting the diagnostic criteria for Alzheimer's disease and related disorders.
  • Patients living in a Protected Living Unit (PLU)
  • If consuming psychotropic medications, they must have been stabilized for 3 months.
  • If consuming level 2 or 3 analgesics, they must have been stabilized for 1 month.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate.
  • Participation in a study on a drug /medical device / care technique that could affect sleep or behavior during the study.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Passive EXPERIMENT

    Measurement of the effects of a personalised music listening session at bedtime (play-list) for 10 days. Each patient is his or her own control. Behavioural and actigraphic data are collected and compared before, during and after the intervention.

    Behavioral: Music intervention - passive listening

  • Active EXPERIMENT

    An intervention based on listening to audio books, led by a therapist for 10 evenings . Each patient is his or her own control and takes part in the entire experiment. Behavioural and actigraphic data are collected and compared before, during and after intervention.

    Behavioral: Audio books intervention - active listening

Interventions

  • BehavioralMusic intervention - passive listening

    Diffusion of familiar music in the bedrooms and living room before bedtime; passive and individual listening.

  • BehavioralAudio books intervention - active listening

    Dynamic audio book listening, akin to active listening while respecting the rhythm of the evening . This type of listening involves concentrating specifically .

06

What researchers measure

Primary outcomes

  1. Sleep duration

    Sleep duration will be measured by actigraphy (bracelet worn by the participants).

    Time frame: Days 1 to 51

Secondary outcomes

  1. Sleep onset and nocturnal awakenings reduction

    Sleep onset latency and number of nocturnal awakenings measured by actigraphy.

    Time frame: Days 1 to 51

  2. Daytime agitation reduction

    Cohen-Mansfield Agitation Inventory score, which assesses 29 items including: non-aggressive physical agitation (1-13), non-aggressive verbal agitation (14-17), physical agitation and aggression (18-26), and verbal agitation and aggression (27-29). A high score reflects intense agitation.

    Time frame: Days 1 to 51

  3. Mood improvement

    Caregiver questionnaire: category scale : for agitation and mood.

    Time frame: Days 1 to 51

  4. Falls number reduction

    Fall questionnaire include in the caregiver questionnaire.

    Time frame: Days 1 to 51

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 22 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Oct 6, 2025
StartActual
Jan 13, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Feb 2028
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07207642
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Jan 13, 2026
Primary completion
Nov 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jan 26, 2026

Study contacts

Isabelle ROUCH, Md
Contact
isabelle.rouch@chu-st-etienne.fr
(0)477127399 ext. +33
Céline BORG, PhD
Contact
celine.borg@chu-st-etienne.fr
(0)477127805 ext. +33
Isabelle ROUCH, Md
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion